Decibel Therapeutics Stock

decibeltx.comHealthcareFounded: 2015Funding to Date: $132.06MM

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine.

Register for Details

For more details on financing and valuation for Decibel Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Decibel Therapeutics.

Register Today

Team

Management Team

Paula Cobb
Chief Operating Officer
John Keilty
Chief Data Sciences Officer
Albert Edge Ph.D
Co-Founder & Scientific Advisory Board Member
Shin-San Michael Su Ph.D
Chief Scientific Officer
Anna Trask
Chief People, Community and Culture Officer
Charles Liberman Ph.D
Co-Founder & Scientific Advisory Board Member
Ulrich Müller Ph.D
Co-Founder & Member of Scientific Advisory Board
Steven Holtzman
Chairman
Leslie Shinobu MD
Chief of Translational Research
Gabriel Corfas Ph.D
Co-Founder & Member of Scientific Advisory Board

Board Members

Craig Muir
Third Rock Ventures
Neil Exter
Third Rock Ventures
Steven Holtzman
Anthony Philippakis MD
GV
Gabriel Corfas Ph.D
Jeffrey Jonas MD
Roger Brown
Ulrich Müller Ph.D
George Scangos Ph.D
Jens Eckstein Ph.D
SR One
Troyen Brennan MD

Other companies like Decibel Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$4.8B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM

News

Decibel Therapeutics announces appointment of biopharmaceutical leader Christine A. Poon to its board of directors.
Decibel Therapeutics, which discovers and develops medicines to treat hearing loss and hearing-related disorders, raised $55M in Series C funding